

NIH AIDS Reagent Program

20301 Century Boulevard Building 6, Suite 200 Germantown, MD 20874 USA

Phone: 240 686 4740 Fax: 301 515 4015 aidsreagent.org

DATA SHEET

Reagent: Anti-HIV-1 gp120 Monoclonal (4G10)

Catalog Number: 2534

Lot Number: 160245

Release Category: D

Provided: 1 mL of culture supernatant

A monoclonal antibody to HIV-1 gp120, specifically to the V3 loop (epitope: **Description:**

RIQRGPGRAFVTIGK)

Host: Mouse

Titer: The user should determine the optimal concentration for any application.

Special

This antibody was produced in cell culture. It originates from a hybridoma. The Characteristics: hybridoma was created by immunizing Balb/c mice with HIV-1 gp120 (aa 308-322)

fused to HBcAG particles. The resulting splenocytes were fused to Ag8653 myeloma cells.

4G10 recognizes HIV-1 gp120 V3 loop peptide RIQRGPGRAFVTIGK (aa 308-322) in ELISA. The antibody inhibits syncytium formation, RT activity, and p24 production in

vitro (100% over 20 days).

Please see the <u>LANL HIV Immunology Database</u> for more information.

Applications: ELISA, Western blot, IFA

Recommended

Storage:

Keep the reagent at 4°C for short term storage and -80°C for long term storage. Avoid

freeze-thaw cycles as reagent degradation may result.

Contributor: Dr. Albrecht von Brunn (Courtesy of CFAR, NIBSC)

Isotype: IgG_1

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.

REV: 06/04/2018 Page 1 of 2 References: von Brunn, A., Brand, M., Reichhuber, C., Morys-Wortmann, C., Deinhardt, F., & Schodel,

F. (1993). Principal neutralizing domain of HIV-1 is highly immunogenic when expressed

on the surface of hepatitis B core particles. Vaccine, 11(8), 817-824. PUBMED

von Brunn A., Reichhuber C., Brand M., Bechowsky B., Gürtler L., Eberle J., Kleinschmidt A., Erfle V., Schödel F. (1993). The principal neutralizing determinant (V3) of HIV-1 induces HIV-1-neutralizing antibodies upon expression on HBcAg particles. Vaccines 93,

Cold Spring Harbor Press; Cold Spring Harbor, New York, 159-165. ARTICLE

NOTE:

Publications should acknowledge the contributor and the Centre for AIDS Reagents. Acknowledgments should read: "The Anti-HIV-1 gp120 Monoclonal (4G10), NIH-ARP# 2534 (CFAR# 3012) was obtained from the Centre for AIDS Reagents, NIBSC, UK, supported by EURIPRED (EC FP7 INFRASTRUCTURES-2012 - INFRA-2012-1.1.5.: Grant Number 31266). www.euripred.eu/ Also include the references cited above in any

publications.

Last Updated June 04, 2018

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.

REV: 06/04/2018 Page 2 of 2